Appeals Court Restores Takeda’s Velcade Patent

Takeda’s patent for its multiple myeloma drug Velcade was restored and extended for five more years after a federal appeals court overturned a district court ruling.

In 2015, the U.S. District Court for the District of Delaware invalidated the patent after Takeda sued several generic drugmakers, including Mylan, Sandoz, Sun Pharma and Hospira, that had registered challenges to the patent with the FDA.

The court made the ruling specifically in the Sandoz case, and the drug’s exclusivity period was slated to end in November. The Federal Circuit court of appeals’ ruling re-establishes exclusivity through 2022.